Navigation Links
Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain
Date:10/31/2011

us tasks such as driving a car or operating machinery. This is to be expected especially at the beginning of treatment, at any change of dosage as well as in combination with alcohol or tranquilizers.
  • NUCYNTA® has not been systematically evaluated in patients with a seizure disorder, and such patients were excluded from clinical studies. NUCYNTA® should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures.
  • The development of a potentially life-threatening serotonin syndrome may occur with use of SNRI products, including NUCYNTA®, particularly with concomitant use of serotonergic drugs such as SSRIs, SNRIs, TCAs, MAOIs and triptans, and with drugs which impair metabolism of serotonin (including MAOIs). Serotonin syndrome may include mental-status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, incoordination) and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea).
  • Withdrawal symptoms may occur if NUCYNTA® is discontinued abruptly. These symptoms may include: anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and rarely, hallucinations. Withdrawal symptoms may be reduced by tapering NUCYNTA®.
  • Pregnancy Category C. There are no adequate and well-controlled studies of NUCYNTA® in pregnant women. NUCYNTA® should be used during pregnancy ONLY if the potential benefit justifies the potential risk to the fetus. NUCYNTA® is not recommended for use in women during and immediately prior to labor and delivery. Neonates whose mothers have been taking NUCYNTA® should be monitored for respiratory depression. NUCYNTA® should not be used during breastfeeding.
  • NUCYNTA® is not recommended in patients with severe renal or hepatic impairme
    '/>"/>

  • SOURCE Janssen Pharmaceuticals Research & Development
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
    2. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
    3. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
    4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
    5. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
    7. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
    8. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
    9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
    10. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
    11. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
    (Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
    (Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
    Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
    ... US Phase II Clinical Trials for Organ Transplantation, ... announces positive Phase I clinical results for,its transplantation ... clinical trials for organ transplantation. , Today LifeCycle ... I clinical trial program of LCP-Tacro, a,proprietary, once-daily ...
    ... Hemispherx Biopharma, Inc.,(AMEX: HEB), a biopharmaceutical company ... new drug entities for pandemic,disease threats, announced ... therapeutic product candidate Alferon-LDO in,combating highly pathogenic ... Alferon-LDO is a low-dose experimental oral formulation,of ...
    Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 2Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 4
    (Date:9/16/2014)... (PRWEB) September 16, 2014 SAMHSA, the federal ... mission a reduction of the impact of substance abuse and ... on the SAMHSA website in September is National Recovery Month, ... honor the gains made by those individuals in recovery. ... to addiction treatment in an effort to help those with ...
    (Date:9/16/2014)... Using a pain clinic as a testing ground, researchers ... first popularized by Toyota in Japan can substantially reduce ... interns and residents. , In a report on the ... Medicine , the researchers adopted the so-called "Just-in-Time" training ... service industries to stem waste and keep complicated operations ...
    (Date:9/16/2014)... R.I. (PRWEB) September 16, 2014 As ... Sunday, Sept. 14, through Saturday, Sept. 20, Amica ... sure children are safe and secure while in the ... the National Traffic Highway Safety Administration (NHTSA), 20 ... not read the instruction manual when installing child restraints. ...
    (Date:9/16/2014)... 2014 Regulatory intelligence (RI), the ... has become a crucial skill for regulatory professionals ... sectors. Regulatory Intelligence 101 , new from ... serves as an essential guide to the basics ... examines available regulatory intelligence tools, both free and ...
    (Date:9/16/2014)... Illegal drug use among teens in the United States is ... Encouragingly, the new study also found that alcohol use, ... people between the ages of 12 and 17 also dropped ... people aged 12 and older across the United States revealed ... among this age group also dropped from 8.9 percent to ...
    Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 2Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:RAPS Publishes Regulatory Intelligence 101 Book 2Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2
    ... apply the chemicals, study shows , THURSDAY, June 18 ... the normal risk of developing a precancerous blood disorder, ... undetermined significance) and characterized by an abnormal level of ... can lead to multiple myeloma, a cancer of the ...
    ... ... term, the continent’s healthcare leadership must be strengthened and expanded at the individual, institutional, ... ... -- To improve health outcomes in Africa over the long term, the continent’s healthcare ...
    ... up at night worrying whether they are going to develop diabetes ... middle age is a lifetime away. As it ... School of Medicine have found that young adults (18 to 30 ... treadmill test -- are two to three times more likely to ...
    ... Arnhem, June 2009 The 4th ESU Master class ... the European School of Urology (ESU) on 27-28 June ... The format consists of three modules. Module 1 is ... ,Immunotherapy and targeted therapies, and module 3 ,Systemic cytotoxic ...
    ... (OTC Bulletin Board: BHRT) a company committed to delivering ... treat heart failure and cardiovascular diseases announced today that ... systems at the American Association of Heart Failure Nurses ... place from June 25 - 27, 2009 at the ...
    ... , ... present never-before released results from two annual surveys at the upcoming DIA Meeting in ... ... for clinical trials information, will present never-before released results from two annual surveys aimed ...
    Cached Medicine News:Health News:Pesticides Linked to Blood Disorder 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 3Health News:Aerobically unfit young adults on road to diabetes in middle age 2Health News:4th ESU master class on medical treatment for urological cancer held in Barcelona, Spain 2Health News:Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 2Health News:Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 3Health News:CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting 2
    Lombart clip-on occluder...
    9 inch double ended with one end black and the other end with 49 holes...
    Double Ended Occluders...
    Long handle occluders are approximately 9 inches long....
    Medicine Products: